Sign In
Buy ARDS
$0.0029
+0 (+0%)
At Close: Jun 03, 2026
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
PARAMUS, N.J.--(BUSINESS WIRE)--Kermode Biotechnologies, Inc., announced that it is actively engaged in discovery to identify the mode of transmission and replication for the ASFV.
Aridis Pharmaceuticals Announces 2020 Fourth Quarter and Year-End Financial Results and Business Update
05:49pm, Tuesday, 30'th Mar 2021
LOS GATOS, Calif., March 30, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to
Aridis Pharmaceuticals Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
08:00am, Friday, 26'th Mar 2021
LOS GATOS, Calif., March 26, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies t
Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants
07:21am, Tuesday, 23'rd Feb 2021
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The comp
LOS GATOS, Calif., Feb. 23, 2021 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to
Aridis Pharmaceuticals Announces Third Quarter 2020 Results
04:05pm, Friday, 20'th Nov 2020
SAN JOSE, Calif., Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel
05:30am, Tuesday, 27'th Oct 2020
SAN JOSE, Calif., Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to t
Albireo's Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Friday, 11'th Sep 2020
Albireo reports positive data from Phase 3 trial. Jazz Pharmaceuticals inks new cancer deal with Redx Pharma.
Aridis Pharmaceuticals Announces Second Quarter 2020 Results
08:05pm, Tuesday, 11'th Aug 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening infections, today reported
Aridis Pharmaceuticals (NASDAQ:ARDS) Upgraded by Zacks Investment Research to “Hold”
01:48am, Sunday, 19'th Jul 2020
Zacks Investment Research upgraded shares of Aridis Pharmaceuticals (NASDAQ:ARDS) from a sell rating to a hold rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, �
We Think Aridis Pharmaceuticals (NASDAQ:ARDS) Can Easily Afford To Drive Business Growth
12:42pm, Wednesday, 15'th Jul 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
H.C. Wainwright Thinks Neovasc's Stock is Going to Recover - Markets
10:13am, Thursday, 02'nd Jul 2020
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Neovasc (NVCN – Research Report) today and set a price
Is the Vanguard Property ETF a good long-term investment?
03:52am, Thursday, 02'nd Jul 2020
Is the Vanguard Australian Property Securities ETF (ASX: VAP) a good long-term investment for ASX dividend income in 2020?
Cel-Sci (CVM) Receives a Buy from H.C. Wainwright - Markets
10:18am, Monday, 29'th Jun 2020
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cel-Sci (CVM – Research Report),
